Precipio Inc (TBIO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Precipio Inc (TBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3451
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Precipio Inc (Precipio), formerly Transgenomic Inc, is a developer and provider of diagnostic tools and services. The company advances personalized medicine for the detection and treatment of cancer, and inherited diseases through its molecular technologies and clinical and research services. It offers ICEme Kits, which finds applications for mutation specific, disease specific and gene specific panels. Precipio uses ICE COLD-PCR, a sensitivity platform technology, which enables adoption of personalized, precision medicine in cancer and other diseases. Transgenomic’S MX-ICP is an amplification technology that suppresses normal DNA and thereby enables the selective amplification of mutations. Its MX-ICP works on sample types that contain DNA, including tissue, blood, urine and saliva or sputum. It operates through its research and development facility located in Omaha, Nebraska, the US. Precipio is headquartered in Omaha, Nebraska, the US.

Precipio Inc (TBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Precipio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Precipio Inc, Medical Devices Deals, 2012 to YTD 2018 10
Precipio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Precipio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Transgenomic To Acquire Clinical Sample Biorepository Assets From Gene Logic For US$0.3 Million 12
Partnerships 13
Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 13
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 14
Transgenomic Enters Into Co-Development Agreement With Medical College of Wisconsin 15
Licensing Agreements 16
LabCorp Enters into Licensing Agreement with Transgenomic 16
Transgenomic Expands Licensing Agreement with Exiqon 17
Equity Offering 18
Transgenomic Raises USD1.2 Million in First Tranche of Private Placement of Shares 18
Transgenomic to Raise up to USD3.5 Million in Public Offering of Shares 20
Transgenomic Raises up to USD2.2 Million in Private Placement of Preferred Stock and Warrant 21
Transgenomic to Raise USD3 Million in Private Placement 22
Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 23
Transgenomic Raises USD7 Million in Private Placement of Shares 25
Transgenomic Completes Private Placement Of Shares For USD8.3 Million 26
Transgenomic Completes Private Placement Of Shares For US$19 Million 27
Debt Offering 28
Transgenomic Raises USD1.2 Million in Private Placement 28
Transgenomic Raises USD0.9 Million in Priavte Placement of Promissory Notes 29
Precipio Inc – Key Competitors 30
Precipio Inc – Key Employees 31
Precipio Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Jul 18, 2018: Precipio announces 213% year-over-year revenue growth in preliminary Q2-2018 results 33
Corporate Communications 34
Aug 09, 2018: Precipio Appoints New Board Member to Replace Departing Director 34
Legal and Regulatory 35
Mar 13, 2018: Precipio Settles Lawsuit with Crede Capital 35
Government and Public Interest 36
Apr 03, 2018: Important JAMA Article Underscores Superiority of Precipio’s Liquid Biopsy Core Technology 36
Other Significant Developments 38
Apr 11, 2018: Precipio Launches ICE COLD-PCR Research Access Program for Cancer Centers 38
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Precipio Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Precipio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Precipio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Precipio Inc, Medical Devices Deals, 2012 to YTD 2018 10
Precipio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Transgenomic To Acquire Clinical Sample Biorepository Assets From Gene Logic For US$0.3 Million 12
Transgenomic Enters Into Co-Marketing Agreement With PerkinElmer For Oncology Diagnostic Test Portfolio 13
Transgenomic Enters Into Co-Development Agreement With Amgen For IVD Test 14
Transgenomic Enters Into Co-Development Agreement With Medical College of Wisconsin 15
LabCorp Enters into Licensing Agreement with Transgenomic 16
Transgenomic Expands Licensing Agreement with Exiqon 17
Transgenomic Raises USD1.2 Million in First Tranche of Private Placement of Shares 18
Transgenomic to Raise up to USD3.5 Million in Public Offering of Shares 20
Transgenomic Raises up to USD2.2 Million in Private Placement of Preferred Stock and Warrant 21
Transgenomic to Raise USD3 Million in Private Placement 22
Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 23
Transgenomic Raises USD7 Million in Private Placement of Shares 25
Transgenomic Completes Private Placement Of Shares For USD8.3 Million 26
Transgenomic Completes Private Placement Of Shares For US$19 Million 27
Transgenomic Raises USD1.2 Million in Private Placement 28
Transgenomic Raises USD0.9 Million in Priavte Placement of Promissory Notes 29
Precipio Inc, Key Competitors 30
Precipio Inc, Key Employees 31
Precipio Inc, Other Locations 32
Precipio Inc, Subsidiaries 32

List of Figures
Precipio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Precipio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Precipio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Precipio Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Precipio Inc (TBIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Essar Oil Ltd-石油・ガス分野:企業M&A・提携分析
    Summary Essar Oil Limited (Essar Oil) is an integrated oil and gas company. The company acquires, explores, develops, and produces oil and gas from its assets. It refines crude oil to produce LPG, naphtha, light diesel oil, Aviation Turbine Fuel (ATF) and kerosene. The company markets its petroleum …
  • XOMA Corp (XOMA):企業の財務・戦略的SWOT分析
    XOMA Corp (XOMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Fresenius Kabi USA LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Fresenius Kabi USA LLC (Fresenius Kabi), a subsidiary of Fresenius Kabi AG, is a pharmaceutical and medical device company which provides lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. It provides products and services to critically and chronically il …
  • GS Engineering & Construction Corp (006360):企業の財務・戦略的SWOT分析
    GS Engineering & Construction Corp (006360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Takashimaya Company, Limited
    Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report Summary Takashimaya Company, Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Panmure Gordon & Co Limited (PMR):企業の財務・戦略的SWOT分析
    Panmure Gordon & Co Limited (PMR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Fujisoft Inc (9749):企業の財務・戦略的SWOT分析
    Fujisoft Inc (9749) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The National Petrochemical Co:企業の戦略的SWOT分析
    The National Petrochemical Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Ceska rafinerska, a.s.-石油・ガス分野:企業M&A・提携分析
    Summary Ceska rafinerska, a.s. (Ceska rafinerska) is a crude oil refining company. It carries out the refining of crude oil, and production of petroleum based products. The company’s product portfolio includes automobile gasoline, diesel oil, aviation fuel, fuel oils, liquefied petroleum gas, heatin …
  • Tosoh Bioscience Inc:企業の製品パイプライン分析2018
    Summary Tosoh Bioscience Inc (TBI), a subsidiary of Tosoh Corp, is a medical device company that offers diagnostic systems. The company provides analyzers, assays, immunoassay solutions, reagent technology, HbA1c solutions, ß-thalassemia testing, and HPLC technology. Its immunoassay solutions compri …
  • F-star Biotechnology Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary F-star Biotechnology Ltd (F-star) is a drug development company that offers novel bispecific antibodies. The company develops immuno-oncology bispecific antibody therapeutics. Its technologies comprise modular antibody technology, a proprietary engine that generates bispecific antibodies; mA …
  • Acumen Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Acumen Pharmaceuticals Inc (Acumen) is a pharmaceutical company that discovers and develops therapeutics and diagnostics services for the treatment of Alzheimer’s disease and other related neurodegenerative conditions. It focuses on development of ADDL (amyloid-beta derived diffusible ligand …
  • Nisshin Seifun Group Inc:企業の戦略・SWOT・財務分析
    Nisshin Seifun Group Inc - Strategy, SWOT and Corporate Finance Report Summary Nisshin Seifun Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Paramo AS:企業の戦略的SWOT分析
    Paramo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Kaiser Foundation Health Plan Inc:企業の戦略的SWOT分析
    Kaiser Foundation Health Plan Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Citius Pharmaceuticals Inc (CTXR):製薬・医療:M&Aディール及び事業提携情報
    Summary Citius Pharmaceuticals Inc (Citius), formerly Trail One Inc is a specialty pharmaceutical company that focuses on the development and commercialization of anti-infective products in adjunct cancer care, and critical care drug products. The company’s proprietary product candidates include Min …
  • Baloise Holding Ltd (BALN):企業の財務・戦略的SWOT分析
    Baloise Holding Ltd (BALN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • East-Central Iowa Rural Electric Cooperative:発電所・企業SWOT分析
    East-Central Iowa Rural Electric Cooperative - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, inf …
  • Pearl Polymers Ltd.:企業の戦略・SWOT・財務情報
    Pearl Polymers Ltd. - Strategy, SWOT and Corporate Finance Report Summary Pearl Polymers Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Veeco Instruments Inc (VECO):企業の財務・戦略的SWOT分析
    Summary Veeco Instruments Inc (Veeco) is a technology company that designs, manufacture and markets thin film and semiconductor equipment. The company offers various products and technologies which include MOCVD systems, precision surface processing system, MBE technologies, and ion beam sputtering. …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆